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Fungal infections are an important cause of morbidity and mortality in immunocompromised patients. Amphotericin B
(AMB), with broad-spectrum antifungal activity, has long been recognized as a powerful fungicidal drug, but its clinical
toxicities mainly nephrotoxicity and poor solubility limit its wide application in clinical practice. The fungal metabolism
along with the host immune response usually generates acidity at sites of infection, resulting in loss of AMB
activity in a pH-dependent manner. Herein, we developed pH-responsive AMB-loaded and surface charge-switching
poly(D,L-lactic-co-glycolic acid)-b-poly(L-histidine)-b-poly(ethylene glycol) (PLGA-PLH-PEG) nanoparticles for resolving
the localized acidity problem and enhance the antifungal efficacy of AMB. Moreover, we modified AMB-encapsulated
PLGA-PLH-PEG nanoparticles with anti-Candida albicans antibody (CDA) (CDA-AMB-NPs) to increase the targetability.
Then, CDA-AMB-NPs were characterized in terms of physical characteristics, in vitro drug release, stability, drug
encapsulation efficiency, and toxicity. Finally, the targetability and antifungal activity of CDA-AMB-NPs were
investigated in vitro/in vivo. The result demonstrated that CDA-AMB-NPs significantly improve the targetability
and bioavailability of AMB and thus improve its antifungal activity and reduce its toxicity. These NPs may
become a good drug carrier for antifungal treatment.
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Amphotericin B (AMB), which has been considered to
associate with ergosterol in fungal cell membranes to
mediate ion-permeable pores, is still one of the most ef-
fective agents for the treatment against systemic fungal
infections [1–3]. However, the association leading to the
elevation of the intracellular Ca2+ concentration can re-
sult in renal tubular cell injury [3]. Recently, new lipid
formulations of AMB have been developed to reduce the
nephrotoxicity and improve the therapeutic index [4, 5],* Correspondence: liangyong20142015@163.com; txiaolong2006@126.com
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provided the original work is properly creditedwhile new lipid formulations still remain limited to be
used mainly due to the high cost.
In recent years, advances in gaining drug potency or
in vivo properties of nanoparticles (NPs) for drug delivery
applications by increasing targetability and environmental
sensing leading to NP property switching and sustained drug
release have been improving the bioavailability of AMB with
few side effects for the treatment against systemic fungal in-
fections. The fungal metabolism and the host immune re-
sponse often cause localized acidity, which results loss of
drug activity in a pH-dependent manner [6, 7]. Fungi can
adjust to local conditions such as ambient pH, temperature,
and nutrient supply through shared metabolic systems in-
cluding the Pal/PacC pathway in Aspergillus sp. and the
RIM101 pathway in Candida sp. to infect tissue [8–10].
Developing systemically available nanodrug carriers
that can target and improve antibiotic properties in thele distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
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improve the treatment of these and potentially other in-
fections [9, 10]. Herein, we developed pH-responsive,
drug-encapsulated, surface charge-switching poly(D,L-
lactic-co-glycolic acid)-b-poly(L-histidine)-b-poly(ethylene
glycol) (PLGA-PLH-PEG) nanoparticles for treating fungal
infections. The PLH segment would become positively
charged under acidic conditions, imparting the PLGA-
PLH-PEG NP surface an overall positive zeta potential,
facilitating interactions with the negatively charged ele-
ments of the fungal cell wall leading to strong multivalent
electrostatic-mediated binding. At the same time, in
order to further increase the targeting efficacy for fungal
infections, we prepared anti-Candida albicans antibody
(CDA)-modified AMB-loaded PLGA-PLH-PEG nano-
particles (CDA-AMB-NPs). As CDA reacts with antigens
presenting at the cell wall of C. albicans, these CDA-
AMB-NPs delivering AMB efficiently are designed to
target to and bind avidly to C. albicans in acidity [11, 12],
reducing the loss of antifungal activity in acidity.
The result demonstrates that CDA-AMB-NPs switched
their surface charge from a negative zeta potential (−3.82 ±
0.53 mV) at pH 7.35 to a positive one (2.81 ± 0.34 mV) at
pH 6.8, yielding a significant increase in targetability and
antifungal efficacy at pH 6.8 compared to pH 7.35 with re-
duced hemolytic activity and cytotoxicity on human renal
tubular epithelial cells.
Herein, the CDA-AMB-NPs might step up the devel-
opment of systemically administered and targeted drug
carriers that can potentially treat systemic candidiasis in-
fection associated with acidity.Fig. 1 Synthesis procedure for forming the PLGA-PLH-PEG copolymer.
End-grafting strategy was employed to form the desired PLGA-PLH-PEG
copolymer. The C-terminal Cys of the PLH block reacts with the
orthopyridyldisulfide-modified end group of PEG to form the PLH-PEG
copolymer and then activates the PLGA-COOH using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide
(NHS). Lastly, PEG-PLH and PLGA-NHS polymers are conjugated using
the N-terminal Lys to form the desired PLGA-PLH-PEG copolymerMaterials and Methods
Materials
All chemical reagents used in this study were of HPLC
grade and were purchased from Sigma-Aldrich, St. Louis,
MO, USA, unless otherwise noted. L-Histidine (His),
AMB, and coumarin 6 were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Thionyl chloride and
PLGA-N-hydroxysuccinimide (NHS) were obtained from
the Graduate School at Shenzhen, Tsinghua University.
L-His was derivatized by introducing a carbobenzoxy
(CBZ) group to the α-amino group; the amino group in
the imidazole ring of Nα-CBZ-L-His was protected with
a dinitrophenyl (DNP) group. Nα-CBZ-N
im-DNP-L-His
was then transformed to N-carboxy anhydride (NCA)
form by thionyl chloride. Acetonitrile and methanol were
purchased from EM Science (Chrom AR, HPLC grade,
Mallinckrodt Baker, USA). All the other chemicals and re-
agents used were of analytical grade and commercially
available. Millipore water was prepared by the Milli-Q
Plus System (Millipore Corporation, Bedford, MA, USA). C.
albicans (ATCC 90029) were obtained from the AmericanType Culture Collection (ATCC; Rockville, MD, USA).
mPEG-OPSS polymer (MW 5000) and mPEG-NH2 (MW
5000) were obtained from Laysan Bio (Arab, AL, USA).
Phosphate-buffered solution (PBS) and fetal bovine serum
(FBS) were purchased from Gibco Co. (Uxbridge, UK).
Polymer Synthesis
Poly(D,L-lactide-co-glycolide)-b-poly(L-histidine)-b-poly
(ethylene glycol) (PLGA-PLH-PEG) was synthesized by
a sequential end-grafting process. First, for poly(L-
histidine)-b-poly(ethylene glycol) (PLH-PEG) synthesis,
NCA was synthesized by thionyl chloride treatment of
Nα-CBZ-Nim-DNP-L-His. Then, ring-opening polymerization
of the NCA was initiated by isopropylamine to produce
the product poly(Nim-DNP-L-His), which was further
coupled with carboxylated PEG to produce NH2-PLH-
PEG diblock copolymer under thiolysis deprotection
using 2-mercaptoethanol [13]. Next, PLGA-NHS and PLH-
PEG were reacted with N,N-diisopropylethylamine (DIEA)
for 24 h at 20 °C. The resulting crude triblock copolymer
PLGA-PLH-PEG was formulated (Fig. 1).
Fabrication of CDA-AMB-NPs and Characterization
Modified emulsion/solvent evaporation techniques were
utilized to form AMB-loaded NPs [14]. In brief, a pre-
weighed amount of AMB powder and 10.0 mg of PLGA-
PLH-PEG copolymer were dissolved in a volume of 5.0 mL
of 15:85 v/v DMSO/ethyl acetate solution by vortexing
and sonication. The resulted nanoparticle suspension was
stirred at room temperature overnight and centrifuged at
25,000 rpm for 20 min. The AMB-loaded NPs were then
hardened by allowing slow organic solvent evaporation
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triple filtration using Amicon Ultra-4 100,000 NMWL
centrifugal filter units (Millipore, Billerica, MA, USA)
using sterile water and freeze-dried using 10 % w/v of
sucrose as a cryoprotectant.
To form CDA-modified NPs, AMB-loaded PLGA-
PLH-PEG copolymer was coupled to CDA using EDC/NHS
chemistry and purified by precipitation and drying in vacuo
[14]. After the conjugation reaction, the CDA-AMB-NPs
were purified by centrifugation at 14,000 rpm× 30 min and
redispersed in phosphate-buffered solution. Finally, CDA-
AMB-NPs were lyophilized for 48 h for further use. As a
model control molecule, coumarin 6 can be entrapped in
PLGA-PLH-PEG NPs for qualitative and quantitative
analyses of cellular uptake by candidiasis cells. CDA-
coumarin 6-NPs were fabricated in a similar manner.
As a fungal infection usually generates weak localized
acidity as far as pH = 6.8 [8–10], the particle size and zeta
potential of the PLGA-PLH-PEG NPs in 6.8 and 7.35 pH-
adjusted PBS were determined by using a Zeta PALS dy-
namic light scattering detector (15-mW laser, incident
beam 676 nm, Brookhaven Instrument Corporation).
PLGA-PLH-PEG NPs were resuspended at 2.5 mg/mL in a
1 %w/v uranyl acetate solution (pH ~5.5), deposited onto
carbon-supported copper TEM grids and dried, and then
detected by a JEOL 200 CX TEM (MIT CMSE). And the
content of AMB loaded in the micelle was quantified by
reverse-phase HPLC. Drug release was conducted by sus-
pending NPs in 4 mL of pH-adjusted PBS, and the drug re-
lease rate was measured by spectrophotometry. The
released drug was quantified at each time point in triplicate.
Drug delivery efficiency in vitro was also detected. 1 × 105
C. albicans cells were incubated with 10 mL of CDA-
coumarin 6-NP solution (equivalent to 1.0 μg/mL coumarin
6) for 12 h at different pH (pH = 6.8 and pH= 7.35) and fi-
nally subjected to flow cytometry analysis to determine the
intracellular drug delivery efficiency of CDA-drug-NPs.Biological Effect of CDA-AMB-NPs
Hemolytic Activity
The hemolytic activity of CDA-AMB-NPs was evaluated
using human red blood cells (RBCs) [15]. Erythrocytes
were washed twice with saline solution and then suspended
in saline at 2 % of hematocrit. Different concentrations of
AMB solution and AMB-incorporated PLGA-PLH-PEG
micelle solution were incubated with properly diluted
RBCs at 37 °C for 1 h. After centrifugation at 800 g for
15 min, the supernatant was analyzed for hemoglobin
at 545 nm using a UV spectrophotometer. The percent-
age of hemolysis was determined as follows: Hemolysis
(%) = [(ODs −ODmin)/(ODmax −ODmin)] × 100, where ODs
is the absorbance of the supernatant from samples incu-
bated with the drugs. Diluted RBCs incubated with PBSand with distilled water were used as minimal (ODmin) and
maximal (ODmax) hemolytic controls, respectively [16].
Determination of Cytotoxicity on HKC
Immortalized human renal tubular epithelial cells (HKC)
were cultured at 37 °C with humidified atmosphere of
5 % CO2 in DMEM/F12 supplemented with 10 % fetal
bovine serum (FBS) and 2 ng/mL mouse epidermal
growth factor and were seeded into 96-well culture plates
(Corning, Schiphol-Rijk, The Netherlands) for 24 h. Sub-
confluent cells (culture surface covering nearly 70 %) were
then exposed to various AMB or AMB formulation con-
centrations (1.0–10.0 μM). As kidney injury molecule-1
(KIM-1) and type I transmembrane glycoprotein neutro-
phil gelatinase-associated lipocalin (NGAL) have been re-
ported to correlate with proximal tubular injury [17, 18],
the cytotoxicity was measured periodically by measuring
KIM-1 and NGAL using immunofluorescence, WB, and
RT-PCR methods to determine early damage caused by
exposure to AMB and AMB formulations. The prime set
for NGAL was forward, 5′-TCA CCT CCG TCC TGT
TTA G-3′ and reverse, 5′-CTC CTT GGT TCT CCC
GTA-3′, and that for KIM-1 was forward, 5′-ACTCCTG
CAGACTGGAATGG-3′ and reverse, 5′-CAAAGCTCA
GAGAGCCCATC-3′. For normalization, the expression
of β-actin was examined: forward, 5′-TGC TTC TAG
GCG GAC TAT GA-3′ and reverse, 5′-CTC GGC CAC
ATT GTG AAC TT-3′ [19].
In Vivo Toxicity Analysis
The toxicities of AMB and AMB formulations were
assessed with BALB/cA mice (7–9 weeks old). The Com-
mittee of Laboratory Animal Welfare and Ethics, Anhui
University of Science and Technology has approved all of
the animal studies. Five healthy mice were chosen for each
route of administration. AMB or AMB formulation was de-
livered through an intravenous (2.0 mg/kg/day for 3 days,
pH = 7.4) route. All animals were monitored through
1 week to determine mortality. Biochemical analyses of
blood urea nitrogen (BUN) and creatinine (Cr) levels were
determined to assess the nephrotoxicity of CDA-AMB-
NPs [16]. And major organs were used for light micro-
scopic evaluation with hematoxylin and eosin (HE) or
IHC to evaluate cytological and histological alterations in-
cluding injury, degeneration, apoptosis, or even necrosis.
In Vitro Antimicrobiological Analysis
Susceptibility test for C. albicans to different drugs was per-
formed by the agar-based E-test method (bioMérieux,
Sweden) with 8.4 g/L RPMI 1640 (RPMI, Sigma Chemical
Co., St. Louis, MO, USA), 1.5 % agar, and 1.5 % glucose,
poured in 110-mm-diameter plates. The plates were inoc-
ulated by dipping a sterile swab into the inoculum suspen-
sion adjusted to the turbidity of a 0.5 McFarland standard
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agar in four directions. The plates were dried at ambient
temperature for 20 min before applying the E-test strips.
The minimum inhibition concentration (MIC) endpoints
were determined after 24 h of incubation at 35 °C. The
MIC was read for different amphotericin B deforms, and
null NPs were used as a blank [20]. Experiments were per-
formed in duplicate.
Detection of Apoptosis Markers in C. albicans
C. albicans spores (1 × 105 cells/mL) were inoculated in
RPMI 1640 medium at 37 °C for 3 h with different anti-
fungal agents (free AMB, AMB-NPs, CDA-AMB-NPs,
10.0 μg/mL) and were incubated for 24 h at 36 °C with
shaking (150 rpm). After incubation for 12 h, C. albicans
cells were harvested and then digested with a lysing en-
zyme mixture (2.0 U of lyticase, 2.5 U of chitinase, 2.0 U
of chitosanase, and 15 mg/mL of lysing enzyme [Sigma])
for 10 h at 35 °C. And the presence of apoptotic markers
was analyzed with annexin V-FITC/PI stains. Then, the
apoptotic and necrotic features in the drug-treated
C. albicans cells were evaluated using fluorescence mi-
croscopy and flow cytometry instrument detection,
respectively.Fig. 2 The physical properties of the CDA-AMB-NPs. a TEM image shows th
b Size distribution of the PLGA-PLH-PEG copolymers detected by DLS. c Z
cationic with decreases in pH in PLGA-PLH-PEG. d 1H-NMR spectrum of thIn Vivo Antifungal Activity
The in vivo therapeutic efficacy of the prepared nano-
particles was tested by a described method [21]. Sixty
20–22-g BALB/c mice (6–8 weeks old) were infected
by inhalation with a volume of 20 μL of PBS contain-
ing 5.0 × 105 contagious C. albicans cells. After 3 days,
all infected mice were randomly divided into four groups.
All groups received the drug intravenously as follows:
Group A received PBS (10.0 mg/kg/day for 4 days,
pH = 7.35); group B received free AMB (10.0 mg/kg/
day for 4 days); group C received AMB-NPs (equivalent
AMB 10.0 mg/kg/day for 4 days); group D received
CDA-AMB-NPs (equivalent AMB 10.0 mg/kg/day for
4 days).
After 2 weeks, the survived mice were anesthetized and
sacrificed. Then, the histopathologic changes and fungal
colony-forming units (CFU) in the liver, kidney, heart, and
right lung were determined.Statistical Analysis
Qualitative data was expressed as means ± SEM. Differ-
ences between groups were assessed using one-way
ANOVA. Differences between paired groups were analysedat the CDA-AMB-NPs were spherical with an average size of 125 nm.
eta potential vs pH demonstrates notable switching from anionic to
e PLGA-PLH-PEG copolymer
Table 1 Characterization of AMB-loaded nanoparticles (n = 3)
Polymer Particle size (nm) PDI EE (%)
PLGA-PLH-PEG(NPs) 109.2 ± 4.1 0.238 –
CDA-AMB-NPs 121.1 ± 3.5 0.215 81.51
PDI polydispersity index, EE entrapment efficiency
Tang et al. Nanoscale Research Letters  (2015) 10:256 Page 5 of 11by Student’s unpaired t test. A significance level of p < 0.05
was used for all comparisons.
Discussion
Polymer Characterization: Morphology, Size, Zeta
Potential, Encapsulation Efficiency, and Release
The physical properties of the CDA-AMB-NPs are dis-
played in Fig. 2 and Table 1. Size distributions of the NPs
analyzed by dynamic light scattering (DLS) were 121.1 ±
3.9 nm, and 121 nm of mean diameter was in the excellentFig. 3 Drug delivery and release efficiency analysis. a Fluorescence micro
CDA-coumarin 6-NPs. b Cumulative release of AMB from CDA-AMB-NPs asize range for accumulating readily in tumor vasculature
due to enhanced retention and permeation effects [20, 21].
The 1H-NMR spectrum demonstrates peaks corresponding
to the PLGA-PLH-PEG triblock copolymers. Proton shifts
in DMSO-d6 (ppm): 1.5 b (-CH3 of LA unit, PLGA), 3.0 b
(-CH2-PLH), 3.5 s (OCH2CH2, PEG), 4.4 b (α-carbon-CH-,
PLH), 4.9 b (-CH2-, GA unit, PLGA), 5.2 b (-CH-LA unit,
PLGA), 6.8 b (imidazole ring H, PLH), 7.6 b (imidazole ring
H, PLH).
To evaluate the zeta potential (ZP; mV) property which
was key to tailoring NP-fungal interactions, CDA-AMB-
NPs were resuspended in PBS with appropriate pH (6.8,
7.0, and 7.35). The results showed that the CDA-AMB-
NPs switched their surface charge from a negative zeta po-
tential at pH 7.35 (ζ = −3.82 ± 0.53 mV, N = 3) to a positive
one at pH 6.8 (ζ = 2.81 ± 0.34 mV, N = 3) (Fig. 2c). Thisscope images (×400) of C. albicans cells after being treated with
t 37 °C in pH 6.8 and pH 7.35 in vitro (mean ± SEM, n = 5)
Table 2 Effect of free AMB and AMB-loaded NPs against C.
albicans
MIC (μg/mL, pH = 7.35) MIC (μg/mL, pH = 6.8)
Free AMB 1.0 ± 0.1 1.0 ± 0.2
AMB-NPs 10.0 ± 0.2 11.0 ± 0.2
CDA-AMB-NPs 11.0 ± 0.2 11.0 ± 0.2
Abbreviations: AMB amphotericin B, MIC minimum inhibitory concentration,
AMB-NPs 1.0 μg/mL equivalent free AMB 0.1 μg/mL, CDA-AMB-NPs 1.2 μg/mL
equivalent free AMB 0.1 μg/mL
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charges from the imidazole group of the PLH with reduc-
tions in pH [22]. Polydispersion (PDI), particle size (nm),
and EE (%) parameters are displayed in Table 1.
Intracellular Drug Delivery and Drug Release Efficiency
Analysis
Green fluorescence (coumarin 6) as the marker for
localization and the uptake and distribution of CDA-
coumarin 6-NPs were detected by flow cytometry. The
flow cytometry analysis of C. albicans cells was carried
out 6, 12, and 24 h after the incubation with CDA-
coumarin 6-NPs. Figure 3a shows that after 12 h of incuba-
tion with CDA-coumarin 6-NPs, the green fluorescence of
CDA-coumarin 6-NPs was visible in both the cytoplasm
and cellular walls. Moreover, the fluorescence intensity of
pH 7.35 was lower than that of pH 6.8.
The in vitro drug release profiles of the freshly prepared
CDA-AMB-NPs in PBS (containing 0.1 %w/v Tween 80)
in the first 10 days are displayed in Fig. 3b. Tween 80 was
applied to improve the solubility of AMB in the PBS and
to avoid the adhesion of AMB onto the tube wall [21, 22].
The AMB release from the CDA-AMB-NPs displayed an
initial burst of 58.3 % in the first 6 days at pH = 6.8, which
was much higher than that at pH = 7.35. A second slow-Fig. 4 Representative photomicrographs of CDA-AMB-NP-treated C. albic
activity of C. albicans as confirmed using annexin V/PI at pH = 7.35 and pH= 6
(red fluorescence) and apoptotic cells (green fluorescence). The experiments werelease phase sustained for up to 18 days, which was pre-
dominantly attributed to the diffusion of the drug. After
18 days, the accumulative AMB release of nanoparticles
reached to 81.4 % at pH = 6.8, which indicates that the
PLGA-PLH-PEG copolymer was capable of displaying
sound drug release at pH = 6.8 (Fig. 3b).
In Vitro Antifungal Activity
To evaluate the antifungal activity of the AMB-loaded
nanoparticles, the minimum inhibitory concentration (MIC)
of free AMB, AMB-NPs, and CDA-AMB-NPs at pH 7.35 or
pH 6.8 was tested with C. albicans. As shown in Table 2, the
MIC of AMB-NPs was similar to that of free AMB at
pH 7.35 or pH 6.8, which indicates that CDA-AMB-NPs
have an antifungal potential similar to that of free AMB.
To investigate whether the drug can effectively induce
apoptosis and necrosis of C. albicans cells, the apoptotic
and necrotic features in CDA-AMB-NP-treated C. albicans
cells were evaluated using annexin V-FITC and PI double-
staining method. Apoptotic cells were stained with annexin
V-FITC, whereas necrotic cells were stained with PI accu-
mulated in the nuclei via membrane permeabilization [21].
Following CDA-AMB-NP (6.0 μg/mL, equivalent AMB
0.5 μg/mL) exposure at 37 °C for 24 h at pH = 7.35, about
60 % of the cells were stained with annexin V-FITC, while
only 30 % of the cells were stained with PI. When treated
with CDA-AMB-NP at pH = 6.8 for the same time, almost
all of the cells were stained with annexin V-FITC, and
about 90 % of the cells were PI positive as shown in Fig. 4.
These results suggest that CDA-AMB-NPs can effectively
induce apoptosis and necrosis in C. albicans cells at pH =
6.8, mainly attributed to the increased targetability medi-
ated by strong multivalent electrostatic attraction and
antibody-antigen binding specificity and affinity effect as
well as an improved drug release efficiency (Fig. 3b) whichans cells. Effects of 12- and 24-h treatment with CDA-AMB-NPs on the
.8, respectively. Annexin V/PI stains show the presence of necrotic cells
re performed in triplicate and repeated three times
Table 3 Hemolytic activity of CDA-AMB-NPs and free AMB
against RBCs
Compound Hemolysis (%)
160 80 40 20 10 5.0 2.5 1.25
Free AMB 100 100 100 75.0 35.0 25.0 5.0 0.0
CDA-AMB-NPs 20.0 5.0 1.0 0.0 0.0 0.0 0.0 0.0
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In Vitro Hemolytic Effects of CDA-AMB-NPs
In order to determine the effect of CDA-AMB-NPs on
hemolytic activity against human erythrocytes, the RBC
lysis induced by CDA-AMB-NPs was compared with that
induced by free AMB. The extent of hemolysis induced
after incubation of RBCs with different formulations of
AMB is depicted in Table 3. Contrary to the potent
hemolytic activity of free AMB, the tested concentrations
of CDA-AMB-NPs exhibited less hemolytic activity to-
ward human erythrocytes (Table 3). Incubation with
5.0 μg/mL of free AMB led to about 20 % RBC lysisFig. 5 AMB deformations induce HKC damage. Immunofluorescence, RT-PC
HKC cells treated with free AMB and CDA-AMB-NPs at 10.0 μM for 48 h. a Imm
was stained with red and NGAL was stained with green. b KIM-1 and NGAL m
were analyzed by Western blot. Data are shown as mean ± S.E.M. *p < 0.01, coafter 24 h; however, when free AMB concentration rose
up to 20.0 μg/mL, the hemolytic ability significantly in-
creased to 70 %. On the contrary, the RBC lysis in the
presence of CDA-AMB-NPs (equivalent to 5.0 and 20.0 μg/
mL AMB) was significantly lower compared with that in
the presence of the corresponding concentration of free
AMB (Table 3). The data indicates the protective role
of NP formulations in preventing the hemolytic effects
of AMB.
Cytotoxicity on HKC
The in vitro cytotoxicity of CDA-AMB-NPs on the im-
mortalized human renal tubular epithelial cell line (HKC)
was evaluated. Free AMB was chosen as reference. The
range of concentrations of AMB (1.0, 2.5, 5.0, and 10.0 μM)
was selected because it corresponds to plasma levels of the
drug achievable in humans [23]. As shown in Fig. 5, HKC
cells treated with free AMB or CDA-AMB-NPs (the drug
concentration is lower than 2.5 μM) for 48 h, fluorescence
almost could not be detected in the two groups. When
AMB was increased to 5.0 μM, both red and green fluores-
cence were detected in HKC, which indicates that HKCR, and Western blot were performed to evaluate the cytotoxicity on
unofluorescence staining with anti-KIM-1 and NGAL antibody. KIM-1
RNA levels were analyzed by RT-PCR. c, d KIM-1 and NGAL protein levels
mpared with the free AMB group
Fig. 6 (See legend on next page.)
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Fig. 6 Nephrotoxicity assessment after treatment of different AMB formulations. a Blood urea nitrogen (BUN) and plasma creatinine (Cr) in mice.
*p < 0.01, vs free AMB; data presented as mean ± SEM. n = 3. b Normal mice showed no abnormality and without KIM-1 or NGAL expression. AMB
treatment showed high level of expression of KIM-1 and NGAL, but CDA-AMB-NP treatment revealed very low level of expression of KIM-1 and NGAL
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AMB (10.0 μM) showed a much stronger intensity of red
and green fluorescence. Moreover, mRNA (RT-PCR, Fig. 5b)
and protein levels (Western blot, Fig. 5c) also indicate that
free AMB causes obvious HKC damage; however, when the
concentration of CDA-AMB-NPs was 10.0 μM, the damage
on HKC was not obvious (Fig. 5b–d). These results suggest
that CDA-AMB-NPs can efficiently reduce the free AMB
drug toxicity on HKC cells that originate from the kidney
in vitro.
In Vivo Nephrotoxicity Study
The nephrotoxicity of AMB has been manifested by renal
insufficiency due to vascular and glomerular disease be-
sides the abnormality in tubular function. As BUN and Cr
are important biochemical markers for clinical renal dys-
function, acute AMB-induced nephrotoxicity is character-
ized by increased BUN and Cr levels. When the mice
were administered intravenously with free AMB once a
day and for 3 days in total, there would be a significant
(*p < 0.01) increase in BUN and Cr levels as compared to
normal mice. But CDA-AMB-NPs led to only slightly
higher BUN and Cr levels than those of normal mice (p >
0.05), indicating lower nephrotoxicity by CDA-AMB-NP
compared with free AMB (Fig. 6a). CDA-AMB-NPs also
revealed minimal vascular and glomerular damages on the
kidney examined by histopathological and immunohisto-
chemical analysis (Fig. 6b).
Therapeutic Efficacy of CDA-AMB-NPs
The treatment of C. albicans-infected mice with CDA-
AMB-NPs compared with controlled animals showed
significant reduction in CFU values in evaluated organs
(lung, spleen, kidney, and liver), especially in the kidney
and spleen. But the therapeutic effect of free AMB was
significantly weaker than that of CDA-AMB-NPs (Table 4).
Compared with free AMB and PBS treatment, CDA-
AMB-NPs effectively eliminated fungi in the kidney,Table 4 The ratio of survived mice and CFU in different organs of in
Log CFU gram tissue (n = 3)
Lung Spleen
Control (untreated) 4.35 ± 0.27 3.08 ± 0.25
PBS 4.29 ± 0.35 3.14 ± 0.21
Free AMB 2.51 ± 0.11* 1.12 ± 0.09*
CDA-AMB-NPs 1.01 ± 0.06*# Nil**
Values are expressed as mean ± SEM from four separate experiments. t test values (
*p < 0.05, **p < 0.01 vs control; #p < 0.01 vs the free AMB group
aThe survival rate 25 days post infection (n = 20)liver, and spleen. And the fungal load in the lungs also
significantly reduced (Table 4 and Fig. 7).
In in vivo studies, the lesions demonstrated diffuse ex-
udative change accompanied by necrosis and granuloma-
tous formation in the control group. Many hyphae could
be found in the lesions. The same pathological changes
also existed in the free AMB treatment group. But the
therapeutic efficacy of CDA-AMB-NPs was detected in
murine candida pneumonia. CDA-AMB-NPs significantly
increased the survival time and were more effective in
reducing the CFU counts in the lungs than free AMB
(Fig. 7).
AMB has been reported to cause hemolysis and cyto-
toxicity [1, 24]. In order to reduce the toxicity of AMB,
we used a nanomaterial which has a slow-release effect
to wrap the drug. The result presented that CDA-AMB-
NPs increased drug targeting, delayed drug release, pro-
longed plasma circulation, altered the physical properties
of the drug, and reduced hemolytic toxicity (Table 3).
The reduction of hemolysis of the free AMB loaded in
PLGA-PLH-PEG may be due to the sustained targeting
release of the drug in monomeric mode, which reduces
the concentration of AMB in the blood, compared with
free AMB [25]. CDA-AMB-NPs were also found to be
significantly less nephrotoxic, as CDA-AMB-NPs signifi-
cantly reduced the expression levels of KIM-1 and NGAL
which mark the damage of the kidney cells [26] and the
BUN and Cr levels in serum. These data demonstrated
that CDA-AMB-NPs have therapeutic superiority to free
AMB.
To investigate the CDA-AMB-NPs’ targetability, we in-
cubated CDA-coumarin 6-NPs and C. albicans together.
The results showed that the green fluorescence on the
fungal cell wall increased over time (Fig. 3a). In acidic con-
ditions, the release speed of AMB from the nanodrug is
more efficient, as CDA-AMB-NPs can more dramatically
induce C. albicans apoptosis and necrosis at pH 6.8 than
free AMB (Fig. 4).fected mice
Survival ratioa
(%, n = 20)Kidney Liver
4.78 ± 0.33 3.41 ± 0.34 0.0
4.75 ± 0.29 3.34 ± 0.33 0.0
1.21 ± 0.26* 1.87 ± 0.25* 55.0
Nil** Nil** 95.0
two-tailed) are significant
Fig. 7 HE analysis. CDA-AMB-NPs and free AMB exhibited different histological patterns of C. albicans invasive pneumonia. Representative microscopic
images of lung histology from groups of five infected mice following 10 days of intravenous therapy with either CDA-AMB-NPs or AMB at 2.0 mg/kg/day
are shown (24 mg of AMB-NPs is equivalent to 2.0 mg of AMB) (×200)
Tang et al. Nanoscale Research Letters  (2015) 10:256 Page 10 of 11At the same time, the treatment of experimental infec-
tion mice with CDA-AMB-NPs resulted in 95 % survival
in contrast to 0 % survival in the control group and only
55 % survival in the free AMB group (Table 4). What is
more, CDA-AMB-NP treatment also significantly reduced
the quantity of pathogens in various organs of the infected
mice. And the living bacterium could even be completely
eliminated in parts of tissues and organs (Fig. 7 and
Table 4). For mice fungal infection of the lungs, both
PAS and target blue staining results showed that after
the treatment of CDA-AMB-NPs, the quantity of fungal
spores in the infected lungs of mice significantly reduced,
the alveolar structure returned to normal, and the edema
subsided. These results showed that CDA-AMB-NPs can
effectively kill fungus, improve lung inflammation and
seepage, and promote lung tissue lesion to return to
normal physiological status and function. All these efficacy
data demonstrated a therapeutic superiority of CDA-AMB-
NPs over free AMB.
Conclusion
The developed CDA-AMB-NPs gave appropriate particle
size, extended release, and zeta potential. Compared with
AMB, the in vitro/in vivo data of the present study against
C. albicans showed that CDA-AMB-NPs had less toxicityand significantly higher antifungal activity, which indicated
that the developed CDA-AMB-NP delivery system may
serve as an effective novel low-dose, less side effect an-
tifungal therapeutic system for AMB.
Further experiment on CDA-AMB-NPs including their
specific molecular mechanism, targetability, and release
mechanism and the efficiency of the loaded drug in fungi-
infected lesions will be conducted to reveal more of their
characteristics. Moreover, a detailed in vivo study is re-
quired before this therapy moves to the bedside. Never-
theless, these results raise interesting possibilities for
future studies.
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